Pulmatrix Stops PUR1900 Phase 2B Study Patient Enrollment And Closing Study, In Agreement With Partner Cipla, To Preserve Cash And Facilitate Strategic Alternatives
Pulmatrix Stops PUR1900 Phase 2B Study Patient Enrollment And Closing Study, In Agreement With Partner Cipla, To Preserve Cash And Facilitate Strategic Alternatives
Pulmatrix 与合作伙伴 Cipla 达成协议，停止 PUR1900 2B 期研究患者入组和结束研究，以保留现金和促进战略选择
Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unmet need and faster path to approval, in exchange for 2% royalty on net sales payable to Pulmatrix
Cipla 将全权负责 PUR1900 的开发，将重点重新放在需求未得到满足且获得批准的更快的市场上，以换取应付给 Pulmatrix 的净销售额的 2% 特许权使用费
Pulmatrix to significantly reduce cash burn and focus on strategic alternatives that leverage the company's promising pipeline, iSPERSE technology and approximately $19 million cash on hand as of 12/31/23
截至23年12月31日，Pulmatrix将大幅减少现金消耗，专注于利用公司前景光明的产品线、iSperse技术和约1900万美元手头现金的战略替代方案